ACELYRIN, INC. Announces Positive Top-line Results from Its - GlobeNewswire
ACELYRIN's Phase 2b/3 trial of izokibep for psoriatic arthritis met the primary ACR50 endpoint at 16 weeks with high statistical significance, showing robust clinical responses and a favorable safety profile. Izokibep demonstrated potential for differentiation in enthesitis resolution and achieved meaningful benefits in severe cases.
Related Clinical Trials
Reference News
ACELYRIN, INC. Announces Positive Top-line Results from Its - GlobeNewswire
ACELYRIN's Phase 2b/3 trial of izokibep for psoriatic arthritis met the primary ACR50 endpoint at 16 weeks with high statistical significance, showing robust clinical responses and a favorable safety profile. Izokibep demonstrated potential for differentiation in enthesitis resolution and achieved meaningful benefits in severe cases.